Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00HAJ
|
||||
Former ID |
DNC006887
|
||||
Drug Name |
Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C49H63FN10O9
|
||||
Canonical SMILES |
CC(C)CCC(C(=O)NC(CC1=CC=C(C=C1)F)C(=O)NC(CC2=CC=CC=C2)C<br />(=O)N)NC(=O)C3CCCN3C(=O)C(CCCN)NC(=O)C(CC4=CC=CC=C4)NC(<br />=O)C5CC(=O)NC(=O)N5
|
||||
InChI |
1S/C49H63FN10O9/c1-29(2)17-22-34(43(63)56-38(27-32-18-20-33(50)21-19-32)45(65)55-36(42(52)62)25-30-11-5-3-6-12-30)53-47(67)40-16-10-24-60(40)48(68)35(15-9-23-51)54-44(64)37(26-31-13-7-4-8-14-31)57-46(66)39-28-41(61)59-49(69)58-39/h3-8,11-14,18-21,29,34-40H,9-10,15-17,22-28,51H2,1-2H3,(H2,52,62)(H,53,67)(H,54,64)(H,55,65)(H,56,63)(H,57,66)(H2,58,59,61,69)/t34-,35-,36+,37-,38-,39-,40?/m0/s1
|
||||
InChIKey |
HXKFHHNEFCZKPG-XRBZTNMESA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | NK-2 receptor | Target Info | Inhibitor | [1] | |
Vasopressin V1a receptor | Target Info | Inhibitor | [1] | ||
Melanocortin-4 receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Vascular smooth muscle contractionhsa04080:Neuroactive ligand-receptor interaction | |||||
Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
Reactome | G alpha (q) signalling eventsR-HSA-388479:Vasopressin-like receptors | ||||
G alpha (q) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (s) signalling events | |||||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. Epub 2006 Jul 28.Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivoactivity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.